skip to main content

Our M&A lawyers are among the most experienced and effective in the world. We represent many of the world's largest publicly traded and privately held companies, as well as leading private equity firms, financial advisors and other financial institutions and investors on their most important mergers, acquisitions and takeover transactions.

Foresite Capital to Acquire Pardes Biosciences

Paul, Weiss is advising MediPacific, Inc., a Foresite Capital Management company, in its acquisition of Pardes Biosciences, Inc., a developer of novel oral antiviral therapeutics for life-threatening diseases, including COVID-19. Under the terms of the agreement, MediPacific will acquire Pardes for at least $2.02 per share in cash and an additional cash amount of up to $0.17 per share, with the final price per share being based on the amount of Pardes’s net cash at closing, plus a non-tradeable contingent value right representing the right to receive 80% of any future monetization of its COVID-19 antiviral portfolio and related intellectual property within five years of closing. The acquisition is expected to close in the third quarter of 2023, subject to certain conditions.

The Paul, Weiss team is led by corporate partners Jeffrey Marell, Austin Pollet and Luke Jennings, and included corporate partner Lindsey Wiersma and counsel Usman Arain, Laura Schnaidt and Jason Tyler; executive compensation partner Andrea Wahlquist Brown; tax partner Matthew Jordan and counsel Patrick Karsnitz; intellectual property partner Jonathan Ashtor; and litigation partner Andrew Gordon and counsel Steven Herzog.

© 2023 Paul, Weiss, Rifkind, Wharton & Garrison LLP

Privacy Policy